With its latest FDA nod, AstraZeneca and Daiichi Sankyo’s Enhertu is now the first available drug that specifically targets HER2-mutant non-small cell lung cancer (NSCLC). It will be available to adult patients who have previously received another systemic therapy. Enhertu was first approved to treat HER2-positive metastatic breast cancer in October 2019, an indication for which it currently holds covered or better status for 62% of all insured lives under the pharmacy benefit. 78% of lives have covered or better access to Enhertu under the medical benefit.
SOURCE: MMIT Analytics, as of 8/22/22